• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长链非编码RNA TYMSOS通过下调ULBP3促进乳腺癌转移和免疫逃逸。

LncRNA TYMSOS facilitates breast cancer metastasis and immune escape through downregulating ULBP3.

作者信息

Zhang Ke-Jing, Tan Xiao-Lang, Guo Lei

机构信息

Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, P.R. China.

Clinical Research Center for Breast Cancer in Hunan Province, Changsha, Hunan Province 410008, P.R. China.

出版信息

iScience. 2023 Aug 7;26(9):107556. doi: 10.1016/j.isci.2023.107556. eCollection 2023 Sep 15.

DOI:10.1016/j.isci.2023.107556
PMID:37664624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10470366/
Abstract

The focus of the study is to examine the function of TYMSOS in immune escape of breast cancer, which is the most frequently diagnosed malignancy among women globally. Our study demonstrated that upregulated TYMSOS was associated with unfavorable prognosis and immune escape in breast cancer. TYMSOS promoted the malignant phenotypes of breast cancer cells, and reduced the cytotoxicity of NK92 cells on these cells. CBX3 was a downstream effector in TYMSOS-induced malignant phenotypes in breast cancer cells. Mechanistic studies showed that TYMSOS facilitated CBX3-mediated transcriptional repression of ULBP3, and it also promoted SYVN1-mediated ubiquitin-proteasomal degradation of ULBP3. TYMSOS promoted cell growth, metastasis, and immune escape via CBX3/ULBP3 or SYVN1/ULBP3 axis. The studies further showed that silencing of TYMSOS repressed tumor growth and boosted NK cell cytotoxicity. In sum, TYMSOS boosted breast cancer metastasis and immune escape via CBX3/ULBP3 or SYVN1/ULBP3 axis.

摘要

该研究的重点是检测TYMSOS在乳腺癌免疫逃逸中的作用,乳腺癌是全球女性中最常被诊断出的恶性肿瘤。我们的研究表明,TYMSOS上调与乳腺癌的不良预后和免疫逃逸相关。TYMSOS促进了乳腺癌细胞的恶性表型,并降低了NK92细胞对这些细胞的细胞毒性。CBX3是TYMSOS诱导的乳腺癌细胞恶性表型中的下游效应因子。机制研究表明,TYMSOS促进了CBX3介导的ULBP3转录抑制,并且还促进了SYVN1介导的ULBP3泛素-蛋白酶体降解。TYMSOS通过CBX3/ULBP3或SYVN1/ULBP3轴促进细胞生长、转移和免疫逃逸。研究进一步表明,沉默TYMSOS可抑制肿瘤生长并增强NK细胞的细胞毒性。总之,TYMSOS通过CBX3/ULBP3或SYVN1/ULBP3轴促进乳腺癌转移和免疫逃逸。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/61903477b93f/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/a726656ac716/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/502e2c05e3f9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/4855179fbc29/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/279b2a8c86bd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/9848d0fa229e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/24b84bcde341/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/905bd980c28e/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/7f245d976882/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/61903477b93f/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/a726656ac716/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/502e2c05e3f9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/4855179fbc29/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/279b2a8c86bd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/9848d0fa229e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/24b84bcde341/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/905bd980c28e/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/7f245d976882/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fd/10470366/61903477b93f/gr8.jpg

相似文献

1
LncRNA TYMSOS facilitates breast cancer metastasis and immune escape through downregulating ULBP3.长链非编码RNA TYMSOS通过下调ULBP3促进乳腺癌转移和免疫逃逸。
iScience. 2023 Aug 7;26(9):107556. doi: 10.1016/j.isci.2023.107556. eCollection 2023 Sep 15.
2
LncRNA TYMSOS is a novel prognostic biomarker associated with immune infiltration in prostate cancer.长链非编码RNA TYMSOS是一种与前列腺癌免疫浸润相关的新型预后生物标志物。
Am J Cancer Res. 2023 Oct 15;13(10):4531-4546. eCollection 2023.
3
IncRNA TYMSOS Promotes Epithelial-Mesenchymal Transition and Metastasis in Thyroid Carcinoma through Regulating MARCKSL1 and Activating the PI3K/Akt Signaling Pathway.长非编码 RNA TYMSOS 通过调控 MARCKSL1 并激活 PI3K/Akt 信号通路促进甲状腺癌的上皮间质转化和转移。
Crit Rev Eukaryot Gene Expr. 2022;33(1):1-14. doi: 10.1615/CritRevEukaryotGeneExpr.2022043838.
4
TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miR-4739.TYMSOS 通过海绵吸附 miR-4739 调控 ZNF703 促进胃癌细胞的增殖、迁移和侵袭。
Cell Biol Int. 2021 Aug;45(8):1710-1719. doi: 10.1002/cbin.11610. Epub 2021 May 11.
5
Construction of lncRNA TYMSOS/hsa-miR-101-3p/CEP55 and TYMSOS/hsa-miR-195-5p/CHEK1 Axis in Non-small Cell Lung Cancer.构建非小细胞肺癌 lncRNA TYMSOS/hsa-miR-101-3p/CEP55 和 TYMSOS/hsa-miR-195-5p/CHEK1 轴。
Biochem Genet. 2023 Jun;61(3):995-1014. doi: 10.1007/s10528-022-10299-0. Epub 2022 Nov 9.
6
The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.UL-16结合蛋白-3表达对癌症患者自然杀伤细胞细胞毒性的调节作用。
Sci Rep. 2014 Aug 20;4:6138. doi: 10.1038/srep06138.
7
TYMSOS-miR-101-3p-NETO2 axis promotes osteosarcoma progression.TYMSOS-微小RNA-101-3p-NETO2轴促进骨肉瘤进展。
Mol Cell Probes. 2023 Feb;67:101887. doi: 10.1016/j.mcp.2022.101887. Epub 2022 Dec 9.
8
FOXM1/lncRNA TYMSOS/miR-214-3p-Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma.FOXM1/lncRNA TYMSOS/miR-214-3p介导的NCAPG高表达与非小细胞肺癌的不良预后和细胞增殖相关。
Front Mol Biosci. 2022 Feb 8;8:785767. doi: 10.3389/fmolb.2021.785767. eCollection 2021.
9
Down-regulation of UL16-binding protein 3 mediated by interferon-gamma impairs immune killing in nasopharyngeal carcinoma.干扰素-γ介导的UL16结合蛋白3下调损害鼻咽癌的免疫杀伤作用。
Am J Transl Res. 2020 Oct 15;12(10):6509-6523. eCollection 2020.
10
Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.长链非编码 RNA SNHG12 通过 HuR/PD-L1/USP8 轴调控非小细胞肺癌免疫逃逸的分子机制。
Cell Mol Biol Lett. 2022 Jun 3;27(1):43. doi: 10.1186/s11658-022-00343-7.

引用本文的文献

1
A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs.用于纠正癌症驱动基因突变的碱基编辑平台揭示了保守的p53转录程序。
Genome Biol. 2025 Jul 22;26(1):217. doi: 10.1186/s13059-025-03667-7.
2
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.将表观遗传调节因子作为克服癌症治疗耐药性的一条有前景的途径。
Signal Transduct Target Ther. 2025 Jul 18;10(1):219. doi: 10.1038/s41392-025-02266-z.
3
Induction of the p21/CDK6 pathway and alteration of the immune microenvironment by the stem cell marker CBX3 in melanoma.

本文引用的文献

1
Immunotherapy in breast cancer: an overview of current strategies and perspectives.乳腺癌免疫治疗:当前策略与前景综述
NPJ Breast Cancer. 2023 Feb 13;9(1):7. doi: 10.1038/s41523-023-00508-3.
2
TYMSOS-miR-101-3p-NETO2 axis promotes osteosarcoma progression.TYMSOS-微小RNA-101-3p-NETO2轴促进骨肉瘤进展。
Mol Cell Probes. 2023 Feb;67:101887. doi: 10.1016/j.mcp.2022.101887. Epub 2022 Dec 9.
3
IncRNA TYMSOS Promotes Epithelial-Mesenchymal Transition and Metastasis in Thyroid Carcinoma through Regulating MARCKSL1 and Activating the PI3K/Akt Signaling Pathway.
干细胞标志物CBX3在黑色素瘤中诱导p21/CDK6通路并改变免疫微环境。
Stem Cell Res Ther. 2025 Feb 11;16(1):63. doi: 10.1186/s13287-025-04179-8.
4
Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.解析致癌网络:C1QTNF1-AS1如何通过miR-34a-5p和糖酵解途径调节骨肉瘤
Front Oncol. 2025 Jan 9;14:1485605. doi: 10.3389/fonc.2024.1485605. eCollection 2024.
5
LINC00365 promotes miR-221-5p to inhibit pyroptosis via Dicer in colorectal cancer.LINC00365通过Dicer促进miR-221-5p抑制结直肠癌中的细胞焦亡。
Acta Biochim Biophys Sin (Shanghai). 2024 Oct 22;57(4):529-541. doi: 10.3724/abbs.2024173.
6
Potential therapies for non-coding RNAs in breast cancer.乳腺癌中非编码RNA的潜在治疗方法。
Front Oncol. 2024 Sep 20;14:1452666. doi: 10.3389/fonc.2024.1452666. eCollection 2024.
7
Unveiling the role of the KLF4/Lnc18q22.2/ULBP3 axis in the tumorigenesis and immune escape of hepatocellular carcinoma under hypoxic condition.揭示 KLF4/Lnc18q22.2/ULBP3 轴在低氧条件下肝癌发生发展及免疫逃逸中的作用。
J Cell Mol Med. 2024 May;28(10):e18411. doi: 10.1111/jcmm.18411.
8
Long Non-Coding RNAs as Regulators for Targeting Breast Cancer Stem Cells and Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.长链非编码RNA作为靶向乳腺癌干细胞和肿瘤免疫微环境的调节剂:生物学特性与治疗潜力
Cancers (Basel). 2024 Jan 10;16(2):290. doi: 10.3390/cancers16020290.
长非编码 RNA TYMSOS 通过调控 MARCKSL1 并激活 PI3K/Akt 信号通路促进甲状腺癌的上皮间质转化和转移。
Crit Rev Eukaryot Gene Expr. 2022;33(1):1-14. doi: 10.1615/CritRevEukaryotGeneExpr.2022043838.
4
Construction of lncRNA TYMSOS/hsa-miR-101-3p/CEP55 and TYMSOS/hsa-miR-195-5p/CHEK1 Axis in Non-small Cell Lung Cancer.构建非小细胞肺癌 lncRNA TYMSOS/hsa-miR-101-3p/CEP55 和 TYMSOS/hsa-miR-195-5p/CHEK1 轴。
Biochem Genet. 2023 Jun;61(3):995-1014. doi: 10.1007/s10528-022-10299-0. Epub 2022 Nov 9.
5
Analysis of Pan-Cancer Revealed the Immunological and Prognostic Potential of CBX3 in Human Tumors.泛癌分析揭示了CBX3在人类肿瘤中的免疫和预后潜力。
Front Med (Lausanne). 2022 Apr 28;9:869994. doi: 10.3389/fmed.2022.869994. eCollection 2022.
6
FOXM1/lncRNA TYMSOS/miR-214-3p-Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma.FOXM1/lncRNA TYMSOS/miR-214-3p介导的NCAPG高表达与非小细胞肺癌的不良预后和细胞增殖相关。
Front Mol Biosci. 2022 Feb 8;8:785767. doi: 10.3389/fmolb.2021.785767. eCollection 2021.
7
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
8
lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment.长链非编码RNA与乳腺癌:从机制识别到临床治疗挑战与机遇的进展
Mol Ther Nucleic Acids. 2021 Aug 19;25:613-637. doi: 10.1016/j.omtn.2021.08.005. eCollection 2021 Sep 3.
9
Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.HLA-G 与 NK 细胞受体 KIR2DL4 的相互作用调控 HER2 阳性乳腺癌对曲妥珠单抗的耐药性。
Signal Transduct Target Ther. 2021 Jun 23;6(1):236. doi: 10.1038/s41392-021-00629-w.
10
Construction and Analysis of the Dysregulated ceRNA Network and Identification of Risk Long Noncoding RNAs in Breast Cancer.乳腺癌中失调的ceRNA网络构建与分析及风险长链非编码RNA的鉴定
Front Genet. 2021 Jun 4;12:664393. doi: 10.3389/fgene.2021.664393. eCollection 2021.